The regulatory approval bolsters the cannabis company’s ambitions to be a top player in the category.
Tilray (NASDAQ:TLRY) has opened a new market for its medical marijuana. The company announced Monday that Portugal’s national healthcare regulator, Infarmed, has granted it authorization to sell its products in that country.
“This is the first time a full quality dossier was required and delivered to obtain market authorization in Europe for a medical cannabis product,” Tilray wrote in the press release trumpeting the news.
– Read the entire article at The Motley Fool.
